Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
Publications
2 shownEfficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo O...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 5,267
- Institution
- Oregon Health & Science University
External Links
Identifiers
- ORCID
- 0000-0003-2409-9001
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.